Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

Starting soon · Phase 3

Conditions studied: Homozygous Familial Hypercholesterolemia

In brief

This study will evaluate the efficacy and safety of zodasiran subcutaneous (sc) injection in participants 12 to \<18 years of age with genetically or clinically diagnosed homozygous familial hypercholesterolemia (HoFH) and low-density lipoprotein cholesterol (LDL-C) ≥116 milligrams per deciliter (mg/dL) on maximally tolerated lipid-lowering therapy.

Key facts

Study ID
NCT07473843
Run by
Arrowhead Pharmaceuticals
People needed
12
Starts
2026-08-01
Expected to finish
2028-08-01
Last updated by the study team
2026-05-29

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.